#United States #San Antonio #Texas Biomed #Biodefense #U.S. Department of War

Texas Biomed Partners with U.S. Department of War to Boost Biodefense

The Texas Biomedical Research Institute, a leading independent entity in the biomedical field focused on combating infectious diseases, has taken a significant step toward enhancing the nation’s biodefense. On July 7, 2026, they announced a Collaborative Research and Development Agreement (CRADA) with the U.S. Department of War (DoW). This partnership is designed to advance the protection of service members and civilians from several emergent and severe biological threats.

Strengthening Collaborative Efforts

The agreement aligns with the DoW's Chemical, Biological, Radiological, and Nuclear Defense (CBRND) capabilities. This program oversees national investments aimed at developing robust diagnostics and medical countermeasures (MCMs) against biological threats. The collaboration establishes a framework aimed at accelerating the development, testing, and validation of these vital medical solutions while also bolstering the nation's preparedness.

Dr. Cory Hallam, a prominent figure at Texas Biomed, expressed pride in the institute's role in supporting the country's biodefense mission. He emphasized the institute's commitment to reducing the interval between scientific insight and operational execution, which is crucial for proactive responses to emerging threats.

Collaborative Partnership Goals

The partnership under the CRADA will see Texas Biomed and the DoW work cooperatively on various MCM projects. These initiatives are intended to safeguard global populations, including U.S. military personnel stationed both domestically and internationally. With high containment research facilities and adherence to Good Laboratory Practice (GLP) standards, Texas Biomed is uniquely positioned to support initiatives mandated by the U.S. Food and Drug Administration (FDA).

The institute hosts one of only seven National Primate Research Centers in the nation, providing expert insights into translational studies and model development, further enhancing its capabilities in addressing biological threats.

A Long-Term Commitment to Resilience

This partnership signifies a long-term investment in national resilience against evolving biological threats, which continue to be a critical concern. Dr. Larry Schlesinger, President and CEO of Texas Biomed, underscored the increasing necessity of alliances such as this, which are pivotal in escalating the nation’s countermeasures not just for today, but for the many decades to come.

About Texas Biomedical Research Institute

With a mission dedicated to protecting global health against infectious and chronic diseases, Texas Biomed operates as a nonprofit entity. The integration of basic research, preclinical testing, and innovative partnerships aids the swift development of diagnostics, therapies, and vaccines for some of the world's most dangerous pathogens. Notably, Texas Biomed was behind the development of the first COVID-19 vaccine, Ebola treatment, and hepatitis C therapy. The organization also emphasizes the education of future bioscience leaders to secure a healthier future for all.

In summary, the collaboration between Texas Biomed and the U.S. Department of War is set to advance the nation's biodefense capabilities, ensuring readiness against both naturally emerging and engineered biological threats. This holistic strategy fortifies the U.S.'s ability to respond to emerging biological risks, which is more crucial than ever in today’s dynamic health landscape.